Key Laboratory of Non-Coding RNA Transformation Research of Anhui Higher Education Institution, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Central Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, China.
BMC Cancer. 2022 Aug 12;22(1):882. doi: 10.1186/s12885-022-09972-9.
Glioblastoma (GBM) is the most common primary intracranial tumor in the central nervous system, and resistance to temozolomide is an important reason for the failure of GBM treatment. We screened out that Solute Carrier Family 2 Member 10 (SLC2A10) is significantly highly expressed in GBM with a poor prognosis, which is also enriched in the NF-E2 p45-related factor 2 (NRF2) signalling pathway. The NRF2 signalling pathway is an important defence mechanism against ferroptosis. SLC2A10 related LINC02381 is highly expressed in GBM, which is localized in the cytoplasm/exosomes, and LINC02381 encoded micropeptides are localized in the exosomes. The micropeptide encoded by LINC02381 may be a potential treatment strategy for GBM, but the underlying mechanism of its function is not precise yet. We put forward the hypothesis: "The micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in GBM." This study innovatively used machine learning for micropeptide to provide personalized diagnosis and treatment plans for precise treatment of GBM, thereby promoting the development of translational medicine. The study aimed to help find new disease diagnoses and prognostic biomarkers and provide a new strategy for experimental scientists to design the downstream validation experiments.
胶质母细胞瘤(GBM)是中枢神经系统中最常见的原发性颅内肿瘤,对替莫唑胺的耐药性是 GBM 治疗失败的重要原因。我们筛选出溶质载体家族 2 成员 10(SLC2A10)在预后不良的 GBM 中表达显著升高,这也富集在核因子红细胞 2 相关因子 2(NRF2)信号通路中。NRF2 信号通路是对抗铁死亡的重要防御机制。SLC2A10 相关的 LINC02381 在 GBM 中高表达,定位于细胞质/外泌体,LINC02381 编码的微肽定位于外泌体。LINC02381 编码的微肽可能是 GBM 的潜在治疗策略,但它的功能的潜在机制尚不清楚。我们提出假设:“LINC02381 编码的微肽通过 GBM 中的葡萄糖转运蛋白 SLC2A10 调节铁死亡。”本研究创新性地将机器学习应用于微肽,为 GBM 的精准治疗提供个性化的诊断和治疗方案,从而推动转化医学的发展。该研究旨在帮助发现新的疾病诊断和预后生物标志物,并为实验科学家设计下游验证实验提供新的策略。